For Healthcare Professionals Outside the US

For patients with BRAF V600 mutation–positive unresectable or metastatic melanoma

For patients with BRAF V600 mutation–positive advanced non-small cell lung cancer (NSCLC)

Tafinlar + Mekinist: The first approved combination therapy for advanced NSCLC with a BRAF V600 mutation1

Efficacy and safety established in a Phase II, 3-cohort, multicenter, non-randomized, open-label study1

Treatment-naïve and previously treated patient cohorts

  • Primary End Point: Overall response rate (ORR) using RECIST 1.1 assessed by the investigator1,2
  • Secondary End Points: Duration of response (DoR), progression-free survival (PFS), and overall survival (OS)1,2

Baseline patient characteristics in the phase II trial (cohorts B and C) 

Baseline characteristics

Occurrence of BRAF V600 mutation supports broad biomarker testing

References: 1. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2017. 2. Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17(7):984-993. 3. Tafinlar [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2017.